<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822432</url>
  </required_header>
  <id_info>
    <org_study_id>P061005</org_study_id>
    <nct_id>NCT00822432</nct_id>
  </id_info>
  <brief_title>Coproporphyrine Isomers and Methotrexate Elimination</brief_title>
  <acronym>COMETH</acronym>
  <official_title>Urinary Ratio of the Coproporphyrins Isomers I and III and Its Relationships With Methotrexate Elimination in Patients With a Lymphoid Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High dose methotrexate (MTX) is responsible of severe toxicity in patients in whom&#xD;
      elimination from plasma is delayed. Factors responsible for MTX accumulation are partly known&#xD;
      but some patients still experience toxicity despite adequate measures being taken. Our&#xD;
      hypothesis is that renal tubular secretion may be impaired in these patients. This study aims&#xD;
      at evaluating the performance of the UCP ratio (urinary ratio of coproporphyrins), a putative&#xD;
      biomarker of tubular secretion, in predicting delayed MTX elimination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MTX is a substrate of MRP2, a renal tubular transporter encoded by the ABCC2 gene. It has&#xD;
      been shown that single nucleotide polymorphisms (SNPs) on the ABCC2 gene are associated with&#xD;
      impairment of MTX elimination. Mutations on the ABCC2 gene are also responsible for the&#xD;
      Dubin-Johnson syndrome, characterised by the absence of a functional MRP2 protein. Apart from&#xD;
      hyperbilirubinaemia, the main biological perturbation observed in this disease is a typical&#xD;
      increase of the urinary ratio of coproporphyrins I (I+ III) (UCP ratio). Our hypothesis is&#xD;
      that the UCP ratio could be used as a biomarker of MRP2's activity, thus predicting MTX&#xD;
      elimination. One hundred patients treated with high dose MTX will be recruited in this&#xD;
      prospective study. Their UCP ratio will be measured before and after MTX administration and&#xD;
      correlated with MTX clearance. A genetic analysis will be conducted to study the five more&#xD;
      frequents SNPs of ABCC2 in each patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MTX concentrations</measure>
    <time_frame>at the end of MTX infusion and every 24-hours until concentrations reach 0,2µM.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The UCP I/(I+III) ratio</measure>
    <time_frame>before and at the end of MTX infusion and at the end of hospitalisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Five polymorphisms of the ABCC2 gene (-24C/T, 1249G/A, 3563T/A, 4544G/A)</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cells count .</measure>
    <time_frame>before MTX infusion and at the end of hospitalisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>before MTX infusion and at the end of hospitalisation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">85</enrollment>
  <condition>Central Nervous System Neoplasms</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <condition>Burkitt Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients aged more than 18 y, hospitalized in the neurology or in the haematology&#xD;
             department at PSP hospital of Paris or in the haematology department at CHU of Tours&#xD;
&#xD;
          -  Who should receive high-dose methotrexate (&gt; 1 g/m2) for one of the following&#xD;
             conditions : Central Nervous System Neoplasms; Lymphoma, Large B-Cell, Diffuse;&#xD;
             Precursor B-Cell Lymphoblastic Leukemia-Lymphoma or Burkitt lymphoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Patients receiving HDMTX (≥1g/m2) for a primitive cerebral lymphoma, a large cell&#xD;
             lymphoma, a lymphoblastic lymphoma, a Burkitt's lymphoma or an acute lymphoblastic&#xD;
             leukaemia,&#xD;
&#xD;
          -  over 18 years old,&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Affiliated to a medical assurance.&#xD;
&#xD;
          -  Able to respect the protocol.&#xD;
&#xD;
          -  Effective contraception for women.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  renal failure,&#xD;
&#xD;
          -  liver failure,&#xD;
&#xD;
          -  hepatic cytolysis,&#xD;
&#xD;
          -  chronic respiratory deficiency,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  breast-feeding,&#xD;
&#xD;
          -  Concomitant medication: phenytoin, probenecid, trimethoprim, phenylbutazone,&#xD;
             salicylates, non steroid anti-inflammatory, yellow fever vaccine.&#xD;
&#xD;
          -  Patient included in another study in the four weeks preceding his inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantal Le Guellec, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU of Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>July 30, 2012</last_update_submitted>
  <last_update_submitted_qc>July 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <keyword>ABC transporters</keyword>
  <keyword>MRP2</keyword>
  <keyword>MTX pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

